Charles Schwab Investment Management Inc. Decreases Position in Pediatrix Medical Group, Inc. $MD

Key Points

• Charles Schwab Investment Management Inc. reduced its stake in Pediatrix Medical Group by 2.9%, selling 33,288 shares and holding approximately 1.31% of the company worth $16.3 million as of the end of the last quarter.
• Pediatrix Medical Group reported earnings per share of $0.53 for the last quarter, surpassing the consensus estimate of $0.42, despite a 7.1% decline in revenue compared to the same quarter last year.
• Institutional investors own 97.71% of Pediatrix Medical Group's stock, with several firms increasing their holdings significantly during the first quarter of the year.

Charles Schwab Investment Management Inc. cut its holdings in Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) by 2.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,124,952 shares of the company's stock after selling 33,288 shares during the period. Charles Schwab Investment Management Inc. owned about 1.31% of Pediatrix Medical Group worth $16,301,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. XTX Topco Ltd purchased a new stake in shares of Pediatrix Medical Group during the 4th quarter valued at approximately $169,000. Principal Financial Group Inc. boosted its holdings in shares of Pediatrix Medical Group by 6.2% in the first quarter. Principal Financial Group Inc. now owns 586,190 shares of the company's stock worth $8,494,000 after acquiring an additional 34,266 shares during the period. GAMMA Investing LLC grew its position in shares of Pediatrix Medical Group by 219.5% in the first quarter. GAMMA Investing LLC now owns 2,569 shares of the company's stock valued at $37,000 after purchasing an additional 1,765 shares in the last quarter. SG Americas Securities LLC raised its stake in shares of Pediatrix Medical Group by 194.0% during the 1st quarter. SG Americas Securities LLC now owns 38,405 shares of the company's stock valued at $556,000 after purchasing an additional 25,343 shares during the period. Finally, Deutsche Bank AG lifted its holdings in shares of Pediatrix Medical Group by 53.1% in the fourth quarter. Deutsche Bank AG now owns 74,023 shares of the company's stock worth $971,000 after buying an additional 25,663 shares in the last quarter. Institutional investors own 97.71% of the company's stock.

Pediatrix Medical Group Trading Up 0.0%

Shares of MD traded up $0.0050 during trading hours on Monday, hitting $17.0150. The company had a trading volume of 955,867 shares, compared to its average volume of 889,355. Pediatrix Medical Group, Inc. has a 52-week low of $10.06 and a 52-week high of $17.67. The company has a quick ratio of 1.80, a current ratio of 1.80 and a debt-to-equity ratio of 0.70. The stock's 50 day moving average price is $13.83 and its 200 day moving average price is $13.96. The firm has a market cap of $1.48 billion, a P/E ratio of 13.19 and a beta of 1.21.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.53 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.42 by $0.11. The business had revenue of $468.84 million for the quarter, compared to analyst estimates of $464.37 million. Pediatrix Medical Group had a return on equity of 18.94% and a net margin of 5.66%.Pediatrix Medical Group's revenue for the quarter was down 7.1% compared to the same quarter last year. During the same period last year, the company earned $0.34 EPS. On average, research analysts predict that Pediatrix Medical Group, Inc. will post 1.38 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently commented on MD shares. Macquarie boosted their price target on shares of Pediatrix Medical Group from $19.00 to $20.00 and gave the company an "outperform" rating in a research report on Thursday, May 8th. Zacks Research raised Pediatrix Medical Group to a "strong-buy" rating in a research note on Monday, August 11th. Finally, UBS Group upped their target price on Pediatrix Medical Group from $16.00 to $16.50 and gave the stock a "neutral" rating in a research note on Thursday, August 14th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, Pediatrix Medical Group currently has a consensus rating of "Moderate Buy" and an average target price of $16.75.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.